Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,001
Total Claims
$5.6M
Drug Cost
980
Beneficiaries
$5,748
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+46%
Cost per patient vs peers
$5,748 vs $3,933 avg
-45%
Brand preference vs peers
28.1% vs 51.2% avg
Brand vs Generic
Brand: 4,703 claims · $5.3M
Generic: 12,051 claims · $340K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 514 | $750K |
| Empagliflozin | 491 | $745K |
| Semaglutide | 193 | $431K |
| Sitagliptin Phos/Metformin Hcl | 250 | $387K |
| Dulaglutide | 174 | $351K |
| Semaglutide | 233 | $339K |
| Dapagliflozin Propanediol | 184 | $305K |
| Insulin Degludec | 234 | $234K |
| Finerenone | 125 | $205K |
| Insulin Aspart | 157 | $171K |
| Insulin Glargine/Lixisenatide | 152 | $165K |
| Linaclotide | 123 | $157K |
| Insulin Degludec | 181 | $100K |
| Icosapent Ethyl | 145 | $98K |
| Exenatide Microspheres | 39 | $75K |
Prescribing Profile
Patient Profile
73
Avg Age
75%
Female
1.32
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data